

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*Complete if Known*

Application Number 10/517,518  
Filing Date December 3, 2004  
First Named Inventor Stefan SPERL  
Group Art Unit 1621  
Examiner Name S. Kumar  
Confirmation No.

Sheet

1

of

2

Attorney Docket Number 2923-671

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
SK	1.	WO	02/074756	A	Pentapham AG	9/26/02	
SK	2.	WO	00/04954	A	Stuerzebecher et al	2/3/00	
SK	3.	DE	199 40 389	A	Wilex Biotechnology GmbH	3/1/01	
SK	4.	DE	100 29 014	A	Univ Schiller Jena	12/20/01	
SK	5.	WO	01/070204	A	Max Planck	9/27/01	
Examiner Signature	/Shailendra Kumar/				Date Considered	09/05/2006	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*Complete if Known*

Application Number	10/517,518
Filing Date	December 3, 2004
First Named Inventor	Stefan SPERL
Group Art Unit	1621
Examiner Name	S. Kumar
Confirmation No.	

Sheet

2


of

2

Attorney Docket Number 2923-671

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SK	6.	Sturzebecher et al., "3-Amidinophenylalanine-based inhibitors of Urokinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 21, November 1, 1999, pgs. 3147-3152.	
SK	7.	Magdolen et al., "Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator", "ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 477, 2000, pgs. 331-341.	
SK	8.	Heechung et al., "Selective Inhibition of Urokinase by Substituted Phenylguanidines:...", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 33, no. 11, 1990, pgs. 2956-2961.	
SK	9.	Sperl et al., "(4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 10, 9 May 2000, pgs. 5113-5118.	
SK	10.	Nienaber et al., "Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 10, 10 March 2000, pgs. 7239-7248.	
Examiner Signature	/Shailendra Kumar/		Date Considered 09/05/2006



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

				Application Number	10/517,518
				Filing Date	December 3, 2004
				First Named Inventor	Stefan SPERL
				Group Art Unit	1621
				Examiner Name	S Kumar
				Confirmation No.	
Sheet	1	of	2	Attorney Docket Number	2923-671

## FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
SK	1.	WO	02/074756	A	Pentapham AG	9/26/02	
SK	2.	WO	00/04954	A	Stuerzebecher et al	2/3/00	
SK	3.	DE	199 40 389	A	Wilex Biotechnology GmbH	3/1/01	
SK	4.	DE	100 29 014	A	Univ Schiller Jena	12/20/01	
SK	5.	WO	01/070204	A 3	Max Planck	9/27/01	
Examiner Signature	/Shailendra Kumar/				Date Considered	08/17/2006	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

Appendix



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	10/517,518
				Filing Date	December 3, 2004
				First Named Inventor	Stefan SPERL
				Group Art Unit	1621
				Examiner Name	S. Kumar
				Confirmation No.	
Sheet	2	of	2	Attorney Docket Number	2923-671

Duplicate

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SK	6.	Sturzebecher et al., "3-Amidinophenylalanine-based inhibitors of Urokinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 21, November 1, 1999, pgs. 3147-3152.	
SK	7.	Magdolen et al., "Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 477, 2000, pgs. 331-341.	
SK	8.	Heechung et al., "Selective Inhibition of Urokinase by Substituted Phenylguanidines:...", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 33, no. 11, 1990, pgs. 2956-2961.	
SK	9.	Sperl et al., "(4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 10, 9 May 2000, pgs. 5113-5118.	
SK	10.	Nienaber et al., "Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 10, 10 March 2000, pgs. 7239-7248.	
Examiner Signature	/Shailendra Kumar/		Date Considered
			08/17/2006